Early stage retina created from human embryonic stem cells – a world first

Article

A team of scientists at UC Irvine (UCI) in California have taken the first step in developing transplant-ready retinas by creating an eight-layer, early-stage retina from human embryonic stem cells.

A team of scientists at UC Irvine (UCI) in California have taken the first step in developing transplant-ready retinas by creating an eight-layer, early-stage retina from human embryonic stem cells.

The study's principal investigator, Hans Keirstead of the Reeve-Irvine Research Centre and the Sue and Bill Gross Stem Cell Research Centre at UCI, said: “We made a complex structure consisting of many cell types. This is a major advance in our quest to treat retinal disease.”

To create the multiple cell types the team used a differentiation technique to direct the stem cells to become specific cell types. Keirstead admitted that the engineering element presented them with the greatest challenge. Microscopic gradients had to be built for solutions to bathe the stem cells in so that specific differentiation paths could be initiated.

“Creating this complex tissue is a first for the stem cell field,” said Keirstead. “Dr Gabriel Nistor in our group addressed a really interesting scientific problem with an engineering solution, showing that gradients of solutions can create complex stem cell-based tissues.

“Creating transplantable retinas from stems cells could help millions of people and we are well on our way. ”

The researchers are reported to now be testing the early-stage retinas in animal models to learn how much they improve vision. Positive results may lead to human clinical trials.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.